Ipamorelin FAQ: the questions physicians hear most
The honest answers to the questions patients actually ask before starting.
TL;DR
- Ipamorelin is a short, selective signal to your pituitary to release a clean pulse of growth hormone.
- Most physicians dose it at bedtime on an empty stomach so the pulse lands inside your natural overnight GH wave.
- It is generally well-tolerated, but it is not FDA-approved and requires a prescription from a licensed prescriber.
What it is
Ipamorelin is a five-amino-acid peptide — a tiny chain of building blocks — that acts as a ghrelin-receptor agonist (in plain English: a key that fits a specific receptor on the pituitary gland and triggers growth hormone release). Think of the pituitary as a small bell at the base of the brain. Ipamorelin is a soft tap that rings it. It was first described in 1998 (Eur J Endocrinol, 1998).
How it works
Imagine a thermostat. The hypothalamus sets the target; the pituitary releases growth hormone (GH) in pulses; the liver makes IGF-1 (insulin-like growth factor-1) in response. Ipamorelin nudges the pituitary side of that system. Unlike older GH-releasing peptides (GHRP-2, GHRP-6), it does not raise cortisol or prolactin in published studies — that is why physicians call it "clean." Pulse, not flood. The body's feedback loops stay intact.
Who asks about it
People come to this FAQ when they are deciding whether to start, when they are mid-protocol and noticing something new, or when they are comparing ipamorelin to CJC-1295. The most common questions are about timing, hunger, side effects, sleep, and stacking — so this post answers each in turn.
What the research says
In short trials, ipamorelin raised GH and IGF-1 without measurable rises in cortisol or prolactin (Eur J Endocrinol, 1998). Reported side effects are usually mild and short-lived: head fullness for the first 20–30 minutes, mild lightheadedness, transient water retention. About 1 in 10 patients in early studies reported headache. Long-term human data is limited; most reviews note small sample sizes and short follow-up.
What to know before considering it
Ipamorelin is not FDA-approved. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. Any use requires a licensed prescriber's evaluation. People with active cancer, untreated retinopathy, or known pituitary disease are typically not candidates. Pregnancy and breastfeeding are also exclusions. Bring an IGF-1 baseline lab before starting and a follow-up at 8–12 weeks.
The Halftime POV
Ipamorelin is one of the best-tolerated peptides in the GH family, but it is not a youth button. We treat it as a maintenance tool inside a larger plan: sleep, training load, lab tracking, and an honest conversation about what is realistic over a 12-week cycle.
Related reading:
- Ipamorelin explained: the selective GH secretagogue
- Why ipamorelin is the "clean" GH peptide
- CJC-1295 + ipamorelin: the most common GH peptide combination
- Ipamorelin side effects: what published studies report
FAQ
Q: What is ipamorelin? A: Ipamorelin is a small five-amino-acid peptide that signals the pituitary gland to release a short pulse of growth hormone. It is selective — it does not raise cortisol or prolactin in the way older GH secretagogues did.
Q: When is ipamorelin usually taken? A: Most physicians dose it at night, before bed and at least 90 minutes after the last meal. The goal is to align the GH pulse with the natural overnight wave, which is when most growth hormone is released.
Q: Does ipamorelin make you hungry? A: Not in most patients. Unlike GHRP-6 and GHRP-2, ipamorelin has a clean appetite profile because it does not strongly activate the ghrelin appetite pathway.
Q: Is ipamorelin FDA-approved? A: No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list. Any use requires a licensed prescriber's evaluation.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is ipamorelin?
Ipamorelin is a small five-amino-acid peptide that signals the pituitary gland to release a short pulse of growth hormone. It is selective — it does not raise cortisol or prolactin in the way older GH secretagogues did.
When is ipamorelin usually taken?
Most physicians dose it at night, before bed and at least 90 minutes after the last meal. The goal is to align the GH pulse with the natural overnight wave, which is when most growth hormone is released.
Does ipamorelin make you hungry?
Not in most patients. Unlike GHRP-6 and GHRP-2, ipamorelin has a clean appetite profile because it does not strongly activate the ghrelin pathway.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list. Any use requires a licensed prescriber's evaluation.
Keep reading
A licensed physician reviews your labs and builds your protocol.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.